Journal
EUROPEAN JOURNAL OF IMMUNOLOGY
Volume 46, Issue 5, Pages 1067-1081Publisher
WILEY
DOI: 10.1002/eji.201545828
Keywords
Autoinflammation; Caspase-1; IL-1 family; Toll receptors
Categories
Funding
- NIH [AI-15614, AR-45584]
- National Research Foundation of Korea [MEST 2012R1A2A1A010017910]
- Konkuk University
- Deutsche Forschungsgemeinschaft [BU 1222/3-3]
- Interleukin Foundation
Ask authors/readers for more resources
IL-37 is unique in the IL-1 family in that unlike other members of the family, IL-37 broadly suppresses innate immunity. IL-37 can be elevated in humans with inflammatory and autoimmune diseases where it likely functions to limit inflammation. Transgenic mice expressing human IL-37 (IL37-tg) exhibit less severe inflammation in models of endotoxin shock, colitis, myocardial infarction, lung, and spinal cord injury. IL37-tg mice have reduced antigen-specific responses and dendritic cells (DCs) from these mice exhibit characteristics of tolerogenic DCs. Compared to aging wild-type (WT) mice, aging IL37-tg mice are protected against B-cell leukemogenesis and heart failure. Treatment of WT mice with recombinant human IL-37 has been shown to be protective in several models of inflammation and injury. IL-37 binds to the IL-18 receptor but then recruits the orphan IL-1R8 (formerly TIR8 or SIGIRR) in order to function as an inhibitor. Here, we review the discovery of IL-37, its production, release, and mechanisms by which IL-37 reduces inflammation and suppresses immune responses. The data reviewed here suggest a therapeutic potential for IL-37.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available